Shortly after a review of tegaserod1 was prepared for Australian Prescriber, one of the editorial staff noticed an advertisement for the drug in a medical newspaper. The advertisement appeared to show a young man and a young woman complaining about their symptoms of irritable bowel syndrome. Unfortunately, the young man would not be able to get relief from tegaserod as it was only approved for women. Without studying the product information, health professionals may not have been aware of this restriction from the advertisement.
I wrote to the Code of Conduct Committee to say the advertisement could be misinterpreted. I did not specify which section of the Code might have been breached, but the Australian Pharmaceutical Manufacturers Association (APMA, now Medicines Australia) identified three possible breaches.
On the day the APMA informed me the complaint would be considered, I was surprised to receive a telephone call from the manufacturer of tegaserod. Obviously the APMA had promptly informed the company of the source of the complaint.
The head of marketing politely discussed the issues I had identified. I was reassured that there had been no intention to misinform health professionals. The manager suggested that as any breach of the Code of Conduct would be aminor technicality it may be appropriate to withdraw my complaint. He also pointed out that the Code of Conduct Committee has a big workload and it would be helpful if the Committee did not have to consider inadvertent breaches.
The manager followed up his telephone call with a civil electronic mail message asking me to consider withdrawing the complaint. If other companies take this very persuasive approach it may help to explain why relatively few complaints from health professionals reach the Code of Conduct Committee.
I was on the verge of withdrawing the complaint when tegaserod started appearing in the general media. The stories hailed tegaserod as a breakthrough treatment and featured Kirstie Marshall (Olympic skier, now turned Victorian MP) as the celebrity sufferer. Unfortunately, the message that tegaserod was only approved for women with a less common form of irritable bowel syndrome was not clear. Perhaps the marketing materials did need clarification? I decided not to withdraw the complaint.
The Code of Conduct Committee found the advertisement had breached all three sections of the Code. In keeping with APMA policy2,I was asked to keep the verdict confidential in case the company appealed the decision. I heard nothing more about the complaint until it was published in the annual report of the Code of Conduct Committee.3
- Tegaserod. Aust Prescr 2002;25:74-5.
- Marley J. Complaints: a personal view. Aust Prescr 1999;22:80.
- Medicines Australia. Code of Conduct Annual Report2002. Canberra: Medicines Australia; 2002.